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Purpose: Venous thrombosis and inflammation are interrelated. P-selectin contributes to 
activation of leukocyte-mediated inflammation. Therefore, we hypothesized that the 
neutralization ofP-selectin would decrease vein wall inflammation and thrombosis. 
Method~. Twelve baboons underwent infrarenal inferior vena caval balloon occlusion to 
induce thrombosis. Two groups of four baboons received neutralizing intravenous 
anti-P-selectin antibody (PSab) GA6 or CY1748 before occlusion and at days 2 and 4. 
Four baboons received saline control injections. One baboon per group was killed at days 
2, 6, and 13, and at 2 months. Analysis included phlebography, ultrasound, gadolinium 
(Gd)-enhanced magnetic resonance venography (reflecting vein wall inflammation), and 
histologic, morphometric, and protein evaluation of the vein wall. Thrombus presence or 
absence was assessed. 
Results. By day 2 in PSab baboons, vein wall Gd enhancement was decreased in the 
mfd-inferior vena cava and the right iliac vein (p < 0.05; GA6 vs control baboons), 
normalizing by 2 months. The mid-inferior vena cava revealed fewer neutrophils and 
total leukocytes in PSab baboons; however, for GA6 in the right iliac vein these decreases 
were not present despite the absence of Gd enhancement; they were decreased with 
CY1748. PSab baboons demonstrated significantly less thrombus than control baboons 
(p < 0.01, GA6 and CY1748 vs control baboons). 
Conclusionr. Anti-P-selectin antibody decreases vein wall inflammation and thrombus 
formation. Inhibition of P-selectin may be useful in venous thrombosis prophylaxis. 
(J Vase Surg 1997;25:816-28.) 
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Deep venous thrombosis (DVT) and its associ- 
ated sequelae remain a prevalent medical problem in 
society today. 1DVT may lead to pulmonary embo- 
lism, which results in nearly 300,000 to 600,000 
hospitalizations per year and an estimated 100,000 
to 200,000 deaths. 1,2 Of patients who survive acute 
DVT, approximately 50% have chronic venous dis- 
ease in which destruction of the vein wall and valves 
leads to the syndrome of chronic venous insufficiency 
(CVI). 3 CVI is associated with disabling edema and 
skin ulceration, which affect 400,000 to 500,000 
individuals in the United States, and skin stasis 
changes that affect an additional 6 to 7 million. ~ It 
has been estimated that 50% to 60% of lower extrem- 
ity ulcerations occur from CVI. 4 In fact, 75% of these 
patients have had a history of recurrent ulceration, 
with nearly 30% having a history of 10 or more 
episodes of ulceration. 4 
A relationship exists between DVT and vein wall 
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inflammation, phlebitis. Inflammation likely contrib- 
utes to destruction of venous valves and vein wall 
leading to chronic changes, venous reflux, and the 
syndrome of CVI. 5,6 Leukocyte adhesion molecules, 
such as P-selectin, that are expressed on the surfaces 
of platelets and activated endothelial cells, may play 
an important role in the interrelationship between 
DVT and the resultant vein wall inflammatory e- 
sponse, r Initially, leukocytes will tether and roll onto 
the vessel wall, then firmly adhere and become acti- 
vated, subsequently emigrating into the vein wall. s,9 
This latter process is driven, in part, by a chemoldne 
gradient present within the vein wall. 9,1° This venous 
inflammatory esponse ultimately eads to the ampli- 
fication and formation of additional thrombus, 
driven partially by the expression of tissue factor on 
the surface ofmonocytes and the exposure ofthrom- 
bogenic subendothelial vein wall collagen by the 
release of cathepsin G from activated neutrophils, in
turn disrupting the endothelial cell barrier, n,12 Pre- 
vious work has shown the importance of P-selectin in 
leukocyte accumulation within thrombi, which con- 
tributes to fibrin deposition during thrombosis. ~3 
In this study, we tested the hypothesis that neu- 
tralization of P-selectin will decrease vein wall in- 
flammation, thrombosis, and thrombus amplification 
in a primate model of inferior vena cava (IVC) 
thrombosis. This was accomplished with passive im- 
munization using two different neutralizing mono- 
clonal antibodies CY1748 and GA6 (Pharmacia &
Upjohn, Kalamazoo, Mich.) to P-selectin and com- 
pared with saline controls. The CYI748 monoclonal 
antibody is a chimeric humanized grafted erivative 
of the murine antibody originally developed at the 
Cytel Corp. This unique antibody was shown to react 
with an epitope of the fifth complement repeat do- 
main of P-selectin using domain deletion and site- 
directed mutagenesis protocols at Cytel. 14 Studies at 
Pharmacia & Upjohn confirm that CY1748 reacts 
with recombinant full length P-selectin, but does not 
bind to an engineered P-selectin receptor globulin 
fusion protein that lacks the complement repeat do- 
mains (Personal communication, D. C. Anderson, 
MD, Pharmacia & Upjohn, Kalamazoo, Mich.). 
GA6 monoclonal antibody was originally described 
by Palabrica. ~3 Mapping studies have shown it to be 
immunoreactive with full-length recombinant P-se- 
lectin, but it does not recognize the P-selectin recep- 
tor globulin fusion protein that lacks the comple- 
ment repeat domains. This confirms that this 
antibody maps to the lectin or the epidermal growth 
factor domain, a binding site clearly distinct from 
that of the CY1748 antibody (Personal communica- 
tion, D. C. Anderson, MD, Pharmacia & Upjohn, 
Kalamazoo, Mich.). 
Using a primate model of venous thrombosis 
(induced by balloon catheter), the IVC and iliac 
veins were examined by contrast phlebography, gad- 
olinium (Gd)-enhanced magnetic resonance venog- 
raphy (MRV), duplex ultrasound imaging, vein wall 
morphometrics, vein wall cytokine production, and 
thrombus formation at intervals after thrombus in- 
duction. We demonstrated that neutralization f P- 
selectin with GA6 decreased vein wall inflammation, 
cytokine production, and thrombus formation. In 
contrast, neutralization of P-selectin with CY1748 
demonstrated similar inhibition of thrombus forma- 
tion but less attenuation fvein wall inflammation as
GA6. However, both neutralizing P-selectin anti- 
bodies inhibited vein wall inflammation ascompared 
with controls. 
MATERIALS AND METHODS 
Twelve juvenile baboons, with a mean weight of 
4.9 kg, were studied in three groups (4 per group). 
One baboon from each group was killed on days 2, 6, 
and 13, and 2 months after initiation of thrombosis. 
These timepoints span the range of acute, subacute, 
and chronic inflammatory changes associated with 
venous thrombosis. The baboons were initially anes- 
thetized with 5 to 10 mg/kg of intramuscular Tela- 
zol (100 mg/ml, Elkins-Sinn, Inc., Cherry Hill, 
N.J.) supplemented with 0.3 ml intravenous (IV) 
Pentothal barbiturate (2.5% solution, Abbott, North 
Chicago, Ill.) before endotracheal isoflurane (1% to 
1.5%) and oxygen (100%) anesthesia. At baseline, 
each baboon underwent right groin venous cutdown 
and insertion ofa 6F silicon balloon catheter (Medi- 
Tech, Boston Scientific Corporation, Watertown, 
Mass.) positioned at the bifurcation of the iliac veins. 
A second 6F catheter was placed through the right 
internal jugular vein mad manipulated to just below 
the level of the renal veins. The location of the iliac 
bifurcation and renal veins was identified by baseline 
contrast ph!ebography. The cephalad balloon was 
inflated to 9 mm, followed by inflation of the caudad 
balloon, isolating an area of stasis between the bal- 
loon catheters. Catheter positioning was confirmed 
by plain film and contrast phlebography. The bal- 
loons were left inflated for 6 hours. During balloon 
inflation, ultrasound examination of the infrarenal 
IVC was performed hourly to confirm the absence of 
blood flow between the catheters, and to note the 
presence or absence of thrombus. In addition, one 
contrast phlebogram was obtained to confirm the 
effectiveness of balloon occlusion. At the end of 6 
)OURNAL OF VASCULAR SURGERY 
818  Downing et al. May 1997 
hours, the balloon catheters were deflated and re- 
moved, without traversing the clot. The femoral 
venotomy was repaired, and the internal jugular vein 
was ligated. The mid-ivC was an area of pure venous 
stasis, whereas the right iliac (RI) vein was an area of 
venous stasis plus catheter presence, presumably 
leading to greater direct vein wall injury. 
At baseline, day 2, and day 4 after thrombus 
initiation, one group of baboons received abolus IV 
injection of anti-P-selectin antibody GA6 (2 mg/  
kg), the second group received a bolus IV injection 
of anti-P-selectin antibody CY1748 (2 mg/kg), and 
the third group received IV saline as control at base- 
line and day 2. The baseline administration was given 
at least 1 hour before balloon occlusion. The dose of 
GA6 and CY1748 was chosen to saturate the P- 
selectin binding sites on baboon platelets and repro- 
duced the dose used in previous rat studies using the 
equivalent antibody for rodents (CY1748) 7,15 i7 and 
was twice the dose used in previous primate studies 
(GA6)) 3,14 We chose to administer the antibodies at 
2 day intervals to take advantage ofthe approximate 
36-hour half-life of the antibodies and did not give 
them after day 4 to be certain that the baboons 
would not develop serum sickness. Telazol (5 to 
10mg/kg) was used at day 2 and day 4 for anesthesia 
before antibody or saline administration. 
Serum levels of P-selectin antibodies were evalu- 
ated in one control, two GA6-treated, and each of 
four CY1748-treated baboons before and after anti- 
body administration. As shown with immunofluores- 
cence (GA6) and immunoassay (CY1748) tech- 
niques, antibody-treated, but not control, baboons 
had detectable s rum levels (above baseline) at day 2 
and day 6 after thrombosis, but no antibody was 
detected intreated baboons at day 13 after thrombo- 
sis induction. Immunofluorescence was performed 
using fluorescence-activated cell sorting analysis of 
baboon serum binding to stimulated human platelets 
using 5 mmol/L ADP and measured in fluorescence 
units. The immunoassay was performed by enzyme- 
linked immunosorbent assay (ELISA) to detect he 
presence of CY1748 in baboon serum. 
Platelet counts and coagulation times (activated 
partial thromboplastin time [aPTT] and thrombin 
clotting time [TCT]) were measured at baseline and 
on subsequent experimental days. Techniques for 
evaluation of the vein wall included: MRV, leukocyte 
morphometric analysis, and cytoldne analysis. 
Thrombus formation was assessed at each experi- 
mental timepoint for each baboon, dividing the IVC 
into a proximal segment (balloon site), mid-IVC 
segment, distal segment (balloon site), bifurcation 
segment, and a RI vein segment (five segments per 
baboon). The presence of any amount of formed 
thrombus was considered a positive result. Assess- 
ment involved a combination of contrast phlebogra- 
phy, duplex ultrasound imaging, and MRV. In addi- 
tion, gross inspection and light microscopy were 
used from sacrifice. In each group, the baboon killed 
at day 2 had five segments analyzed, the baboon 
ldlled at day 6 had 10 segments analyzed (inclusive of 
studies at day 2 and day 6), the baboon ldlled at day 
13 had 15 segments analyzed (inclusive of studies at 
days 2, 6, and 13), and the baboon ldlled at 2 months 
had 20 segments analyzed (inclusive of studies at 
days 2, 6, 13 and 2 months). Therefore, for each 
group of baboons, there were 50 segments evalu- 
ated, reflecting all of the available 6mepoints studied. 
Imaging analysis. Phlebography of the iliac 
veins and IVC was performed at baseline, after bal- 
loon deflation, and at days 2, 6, 13 and 2 months to 
document the presence or absence of thrombus. A
22-gauge IV catheter was placed into the superficial 
saphenous vein in the posterior calf region or in the 
femoral vein. Five to ten milliliters of the contrast 
agent iothalamate meglumine 600 mg/ml (Conray, 
Malinckrodt, St. Louis) was used along with a mobile 
x-ray unit (IICD2-2, General Electric, Milwaukee, 
Wis.). Duplex ultrasound imaging was used during 
balloon inflation to document the lack of IVC flow 
between the balloons. 
All baboons underwent baseline and interval 
MRV imaging studies up to the time of death on 
days 2, 6, 13 and 2 months using a 1.5-Telsa super- 
conducting magnet (G.E. Medical Systems) and an 
extremity coil with 5.4 or 5.5 software. Imaging 
sequences included time-of-flight (TOF), inversion 
recovery (I/R), T2-weighted, and Tl-weighted pre- 
and post-Gd-enhancement. A  initial Tl-weighted 
locator image was performed in the coronal plane, 
whereas all subsequent imaging was performed inthe 
axial plane. Imaging began superior to the renal veins 
and extended own to the distal extent of the lilac 
veins. Imaging parameters were as follows: TOF 
(TR, 47 milliseconds; TE, 9 milliseconds; flip angle, 
60 degrees), T2 (TR, 4000 milliseconds; TE, 18 and 
108 milliseconds), I /R  (TR, 4000 milliseconds; TE, 
36 milliseconds; TI, 150 milliseconds) and T1 (TR, 
300 milliseconds; TE, 16 milliseconds). Gd-en- 
hanced imaging was the last sequence performed, by 
administering anIV bolus injection of gadopentetate 
dimeglumine (0.2 mg/kg, Magnevist, Berlex Labs, 
Wayne, N.J.). 
Regions of interest of the IVC and RI vein TOF 
sequences were selected, and the presence or absence 
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of thrombus was noted. I /R  permitted calculation of 
the bright signal intensity (quantified in mm 2) of the 
vein wall and perivenous tissue, reflecting edema, is
Gd enhancement, also quantified in mm z using T1- 
weighted post-Gd sequences, reflected vein wall and 
perivenous inflammation) 9 
Gross analysis at sacrifice. On the day of death, 
a midline laparotomy was performed with identifica- 
tion of the infrarenal IVC and iliac veins. IV heparin 
sulfate (1.0 ml, 1000 U/ml, Elldns-Sinn) was ad- 
ministered just before death to prevent the develop- 
ment of acute thrombus formation during vein ma- 
nipulation. Using careful dissection, the IVC, 
bilateral iliac veins, and superior vena cava were har- 
vested and grossly inspected for the presence or ab- 
sence of clot. On removal the IVC was photo- 
graphed and then sectioned into three portions: a 
proximal balloon site segment, a mid-IVC segment, 
and a distal balloon site segment. All specimens, 
including the RI vein, were then sent for histologic, 
morphometric, and cytoldne analysis. The pulmo- 
nary arteries were inspected, confirming the absence 
of pulmonary embolism in all baboons. 
Histologic and morphometric analysis. Leu- 
kocyte infiltration into the vein wall was evaluated by 
morphometric analysis of the mid-IVC and RI areas. 
Morphometrics were performed by counting leuko- 
cytes in hematoxylin and eosin-stained segments of 
tissues, with five sections per segment) ° Each vein 
wall was assessed for the number and subset of leu- 
kocytes in five randomly selected high-power fields 
(1000×). To eliminate selection bias, these fields 
were selected at equidistant locations around the 
vein wall, and were chosen in exactly the same fash- 
ion for all baboons in all groups. Morphometric 
analysis began at the thrombus-vein wall interface 
and extended the width of 1 ~m. Using standard 
morphologic criteria, including cell size, cytoplasmic 
content, and nuclear size, cells were identified as 
neutrophils, monocytes/macrophages, or lympho- 
cytes. Cell identification has been previously vali- 
dated using antibodies to neutrophils and monocytes 
by immunohistochemical analysis? ° Morphometric 
values of the IVC and RI vein were computed as rates 
of change from the control SVC for each individual 
baboon and then combined for each antibody or 
saline treatment. Values in the IVC or RI vein less 
than SVC thereby resulted in a negative value for the 
vein wall being evaluated. 
Cytokine analysis. ELISA allowed the quantifi- 
cation of cytoldnes in vein wall tissue using previ- 
ously described techniques. 1° At death, a section of 
vein was processed after emoval of thrombus. Initial 
tissue homogenization f vein wall segments was 
performed in a buffer consisting of 1X phosphate- 
buffered saline solution (PBS) with 2 mmol/L phe- 
nylmethylsulfonyl fluoride and 1 ixg/ml of each of 
the following: pepstatin A, leupeptin, aprotinin, and 
antipan (Sigma Chemical Co., St. Louis). The sus- 
pension was subsequently sonicated on ice for 30 
seconds, centrifuged at 1500g for 10 minutes, and 
filtered through a 1.2 ~m syringe filter. Immunore- 
active cytoldne levels were quantified using specific 
ELISAs as previously described, x 0Flat-bottomed 96- 
well microtiter plates were coated with 50 ixl per well 
with specific rabbit anti-cytoldne antibody (ng/txl in 
0.6 mol/L NaC1, 0.26 mol/L H3PO4, and 0.08N 
NaOH, pH 9.6) for 16 hours at 4°C and then 
washed. Microtiter plate nonspecific binding sites 
were blocked with 2% bovine serum albumin in PBS 
and incubated for 60 minutes at 37 ° C. Plates were 
then washed three times, and diluted (1:5 and 1:10) 
specimen (50 ~1) in duplicate was added, followed by 
incubation for 60 minutes at the same temperature. 
Plates were then washed aaa additional three times, 
followed by the addition of 50 Ixg per well of biotin- 
ylated rabbit anticytoldne antibody (3.5 ng/~l in 
PBS, pH 7.5, 0.05% Tween-20, and 2% fetal calf 
serum), and were incubated for 45 minutes at 37 ° C. 
These secondary antibodies were specific for the cy- 
tokine being tested, with no cross-reactivity oother 
cytokines found. Cytokines evaluated included the 
CXC chemokines interleukin (IL)-8 and platelet fac- 
tor (PF)-4, the CC chemokine monocyte chemotac- 
tic protein (MCP)-I, in addition to IL-6 and IL-1 
receptor antagonist protein (IRAP). Plates were re- 
washed three times, followed by the addition of 
streptavidin-peroxidase conjugate (1:5000; 100 ~1 
per well, Bio-Rad Laboratories), incubated for 30 
minutes at 37 ° C, rewashed , and followed by the 
addition of the chromogen substrate o-phenylenedi- 
amine dihydrochloride (100 txl per well). The plates 
were then incubated at room temperature to the 
desired extinction, terminating the reaction with 50 
ixl per well of 3 mol/L H2SO 4 solution. Plates were 
read at 490 nm in an ELISA plate reader. Standards 
were 1/2 log dilutions of the cytoldnes from 1 
pg/ml to 100 ng/ml. The sensitivity of the ELISAs 
was >50 pg/ml. 
Statistical evaluation and animal use. Statis- 
tical evaluations included mean -+ SEM, unpaired 
Student's t tests, and analysis of variance (ANOVA). 
When an ANOVA was significant (p -< 0.05), direct 
comparisons were then made between antibody 
treated groups and the control group. For Gd-MRV 
and I /R  results (Tables I and II), there were four 
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Table I. Gd enhancement, expressed in mm 2, as marker of vein wall and perivenous 
tissue inflammation 
Base (n = 4) 2 day (n = 4) 6 day (n = 3) 13 day (n = 2) 2 mo (n = 1) 
IVC 
Control 4 ± 3 26 ± 6 22 ± 7 14 ± 9 4 
GA6 10±3 6±2"  4±2 7±0 5 
CY1748 0±0 8 ±7 10± 10 0±0 0 
ANOVA 0.03 0.05 0.27 0.30 
RI vein 
Control 6 ± 3 65 ± 14 43 -+ 17 69 ± 27 4 
GA6 19 ± 11 18 ± 6* 31 -+ 20 13 ± 3 3 
C¥1748 16 ± 4 37 ± 12 58 ± 28 21 ± 1 16 
ANOVA 0.40 0.04 0.53 0.15 
*p < 0.05 (by t test, compared with control). 
studies at baseline and day 2, three studies at day 6, 
two studies at day 13, and one study at 2 months. 
Each group reflected the fact that all baboons were 
studied at every timepoint until their death and in 
each group, one baboon was sacrificed at day 2, day 
6, day 13, and 2 months. For morphometrics (Table 
III), the specimens were obtained at death and com- 
bined for each group (n = 4). X 2 analysis was used to 
analyze segments positive for thrombus (Table IV), 
and cytoldnes were analyzed by combining the IVC 
and RI vein values at sacrifice for each group (n = 4). 
Regression analysis was performed between MRV 
and morphometric analysis with both absolute cell 
counts and counts adjusted for the SVC as control. 
Significance was defined as a p value less than or 
equal to 0.05. M1 baboons used in this study were 
housed and cared for in the University of Michigan 
Unit for Laboratory Animal Medicine under the di- 
rection of a veterinarian according to the "Principles 
of  Laboratory Animal Care" (formulated by the Na- 
tional Society for Medical Research) and Guide for 
the Care and Use of Laboratory Animals (NIH Pub- 
lication No. 86-23, revised 1985). The protocol was 
approved by the University of Michigan Committee 
on the Use and Care of  Animals (UCUCA, #5165- 
5637A). 
RESULTS 
Imaging analysis. Phlebography and duplex ul- 
trasound imaging confirmed normal IVC and iliac 
veins before balloon insertion in all baboons. Phle- 
bography and ultrasound emonstrated the absence 
of flow between the balloon catheters during infla- 
tion, and both techniques were used after balloon 
deflation and subsequently to document he pres- 
ence or absence of clot. Thrombus of any amount in 
the area of the mid-IVC between balloons, an area of 
pure venous tasis, was noted in three of four control 
baboons, but only one of four baboons in each of the 
P-selectin antibody groups. For the RI vein, an area 
of stasis plus direct catheter presence, thrombus of 
any amount was noted in all four control baboons, 
two of  four GA6Ctreated baboons, and three of four 
CY1748-treated baboons. Thrombus extended 
along the tract of the catheter, whereas no thrombus 
was noted in the left iliac veins of  any baboon in any 
group. 
Concerning MRV, Gd enhancement, a marker of 
inflammation, was only noted in the presence of 
adherent thrombus. Two days after catheter removal, 
Gd enhancement of the mid-IVC, the area of pure 
stasis injury, was significantly less in the anti-P-selec- 
fin-treated baboons as compared with the control 
baboons (control, 26 -+ 6; GA6, 6 -+ 2; CY1748, 
8 + 7; ANOVA, p = 0.05; Table I). Comparing the 
controls specifically with the GA6-treated group at 
day 2 revealed a significant difference (p = 0.02). 
There was no significant difference between the con- 
trol baboons and the CY1748-treated baboons at 
day 2 (p = 0.09). By day 6 the GA6 antibody was 
more effective than CY1748, but both neutralizing 
P-selectin antibodies were more effective than con- 
trol (control, 22 + 7; GA6, 4 + 2; C¥1748, 10 -+ 
10). However, no significant differences were noted 
between the three groups by ANOVA. By day 13 
both antibodies had decreased enhancement back to 
and below baseline, with no significant differences 
noted between the three groups by ANOVA (con- 
trol, 14 -+ 9; GA6, 7 + 0; CY1748, 0 + 0). Thus in 
the mid-IVC, an area of stasis only, both antibodies 
were effective in limiting the amount of Gd enhance- 
ment, but the GA6 antibody was better than the 
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Fig. 1. Representative in wall histologic pattern of control baboons, GA6-treated baboons, 
and CY1748-treated baboons at day 2. In the control baboon (A, original magnification, 
2007<), neutrophils (closed arrows) were found localizing at the vein wall/thrombus interface 
(open arrows) and extending into the vein wall from both the luminal and adventitial sides of the 
vein wall. In the majority of GA6-treated baboons (B, original magnification, 200×), no 
thrombus was identified in the lumen and the vein wall was devoid of a dense inflammatory cell 
influx. In the CY1748-treated baboon (C, original magnification, 200×), similar findings were 
noted as were found in the GA6-treated group. However, in one of the CY1748-treated 
baboons (day 6), the proximal IVC (D, original magnification, 400 × ) demonstrated numerous 
neutrophils ined up at the vein wall endothelium interface (open arrows), which did not fully 
traverse into the vein wall. n, Neutrophils; w, wall; L, lumen; t, thrombus. 
CY1748 antibody at day 2 and day 6 after thrombo- 
sis. Importantly, although there was a difference by 
ANOVA between the groups at baseline, no differ- 
ences between either GA6 or CY1748 and control 
was found. 
In the RI vein where there was venous tasis plus 
direct catheter presence with injury, the GA6 anti- 
body group had less Gd enhancement compared 
with the CY1748-treated group at day 2 (control, 
65 -+ 14; GA6, 18 _+ 6; CY1748, 37 -+ 12; ANOVA, 
p = 0.04). Comparing the control group with the 
GA6 treated group at day 2 revealed a significant 
difference (p = 0.02), whereas there was no signifi- 
cant difference between the control and CY1748- 
treated group at this timepoint or at subsequent 
timepoints. By day 6, the three groups had compara- 
ble Gd enhancement (control, 43 + 17; GA6, 31 + 
20; CY1748, 58 + 28). However, by day 13 both 
antibody-treated groups were below the control 
value (control, 69 + 27; GA6, 13 + 3; CY1748, 
21 + 1). Thus in areas of stasis plus direct catheter 
presence with injury, the GA6 antibody appeared 
better in preventing Gd-enhancement as compared 
with the CY1748 antibody. At baseline, there were 
no significant differences between the groups by 
ANOVA. 
The amount of edema involving the IVC wall 
(measured as the area ofperivascular bright signal on 
I /R)  at day 2 was less bright in both anti-P-selectin 
treated groups as compared with the control ba- 
boons (control, 21 + 5; GA6, 12 + 9; CY1748, 
12 + 7; ANOVA, p = ns; Table II). Although not 
significant, this trend continued at days 6 and 13. 
However, when the RI vein was evaluated, the GA6 
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Table II. I /R  bright signal, expressed in mm 2, as marker of vein wall and perivenous tissue edema 
Base (n = 4) 2 day (n = 4) 6 day (n = 3) 13 day (n = 2) 2 mo (n = i) 
IVC 
Control 7 -+6 21 +- 5 15 ±2 5 ±2 2 
GA6 1± 1 12 ±9 12-+ 12 3±3 5 
CY1748 4+-4  12 ±7 7 -+7 0±0 0 
ANOVA 0.56 0.66 0.81 0.29 
RI vein 
Control 6 _+ 3 75 + 21 47 ± 10 24 _+ 13 1 
GA6 13±6 13±2"  11±6"  8±0 14 
CY1748 2 ± 2 48 ± 19 39 ± 16 6 ± 6 0 
ANOVA 0.31 0.02 0.05 0.08 
*p < 0.05 (by t test, compared with control). 
Table II I . Vein wall intima and media 
morphometrics (mean number of cells found 
in five high power fields minus superior vena 
cava value as control 
Neutrophils Monocytes Lymphocytes Total 
(n= 4) (n= 4) (n= 4) (n= 4) 
WC 
Control 11 + 3 9 + 1 4 + 3 24 _+ 5 
GA6 3 + 1" 10±3 -2  + 1 11-+4 
CY1748 8±4 10_+4 1± 1 20_+7 
ANOVA 0.19 0.91 0.01 0.29 
RI vein 
Control 11 ± 3 12 -+ 3 2 ± 2 25 -+ 2 
GA6 24 + 11 9 ± 4 -4  + 1" 29 +- 12 
CY1748 6±3 5 ± 1 5 ±4 16+_4" 
ANOVA 0.23 0.41 0.17 0.33 
*p < 0.05 (by r test, compared with controls). 
treatcd group had less evidence of edema as com- 
pared with the CY1748 treated group (control, 75 -+ 
21; GA6, 13 _+ 2; CY1748, 48 _+ 19; p = 0.02 for 
control vs GA6, p = ns for control vs CY1748). This 
trend continued at day 6 (control, 47 -+ 10; GA6, 
11 _+ 6; CY1748, 39 -+ 16; p = 0.05 for control vs 
GA6; p = ns for control vs CY1748). Thus not only 
was GA6 more effective than CY1748 in inhibiting 
Gd-enhancement i  the area of stasis plus catheter 
presence with injury, but it also was more effective in 
inhibiting vein wall edema t day 2 and day 6. Impor- 
tantly, for both the IVC and RI vein, no baseline 
differences were noted by ANOVA. 
Histologic evaluation. At day 2 after thrombo- 
sis, in control baboons, neutrophils were found at 
the thrombus-vein wall interface and extending into 
the vein wall from both the luminal and adventitial 
sides of the vein wall (Fig. 1, A). Later timepoints 
(day 6 and day 13) revealed a greater influx ofmono- 
cytes, macrophages, and fibroblasts with a decline in 
neutrophils. Examination of groups treated with an- 
ti-P-selectin antibody revealed vein walls essentially 
devoid of inflammatory cells (Fig. 1, B and C) except 
for the RI vein in the GA6 group. Few neutrophils, 
monocytes, or macrophages were appreciated as 
compared with the matched specimens. Interest- 
ingly, in one of the CY1748 treated baboons, neu- 
trophils were seen lining the endothelium of the 
proximal IVC, but without evidence for emigration 
into the vein wall (Fig. 1, D). 
Morphometrics.  In the mid-IVC of the control 
baboons, the average change in total leukocytes in 
the IVC from control SVC vein wall was 24 -+ 5 
(Table III) with an absolute leukocyte differential of 
l l  +- 3 neutrophils, 9 +- 1 monocytes, and 4 -+ 3 
lymphocytes. In the GA6-treated group, there was 
an increase of 11 + 4 total leukocytes, which was not 
significantly different as compared with control ba- 
boons. However, the absolute differential revealed 
3 + 1 neutrophils, l0 -+ 3 monocytes, and -2 --- 1 
lymphocytes. These findings revealed a significant 
difference in neutrophil influx between the control 
baboons and the GA6-treated group (p = 0.04), 
although the ANOVA between the three groups was 
not significant. In addition, GA6 appeared to de- 
crease lymphocyte influx, with the ANOVA between 
the three groups being significant (ANOVA, p = 
0.01). The CY1748-treated group revealed an in- 
crease of 20 + 7 total eukocytes in the IVC wall with 
a differential of 8 -+ 4 neutrophils, 10 -+ 4 mono- 
cytes, and 1 _+ 1 lymphocytes. Although lower (ex- 
cept for monocytes), these values were not signifi- 
candy different as compared with control baboons. 
Of note, thc changes in monocyte counts appeared 
independent of the changes in neutrophil counts. 
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Table IV. Vein wall segments positive for thrombus 
All  IVC  + R I  Mid- IVC Al l  IVC  Balloon site R I  
Control 29/50 (58%) 6/10 (60%) 19/40 (48%) 8/20 (40%) 10/10 (100%) 
GA6 15/50 (30%)'~ 1/10 (10%)* 10/40 (25%) 7/20 (35%) 5/10 (50%)* 
CY1748 15,(50 (30%)~ 1/10 (10%)* 9/40 (23%)* 6/20 (30%) 6/10 (60%)* 
*p < 0.05 (by X 2 compared with control). 
"~p < 0.01 (by X 2 compared with control). 
Examination of the RI vein wall in control ba- 
boons revealed an increase of  25 + 2 total cells with 
i1 ± 3 neun'ophils, 12 ± 3 monocytes, and 2 + 2 
lymphocytes (Table III). Interestingly, the GA6- 
treated group revealed a larger increase in total in- 
flammatory cells, as compared with the control 
groups (total leukocytes, 29 + 12) with a absolute 
differential of 24 ± 11 neutrophils, 9 -+ 4 mono- 
cytes, and -4  2 1 lymphocytes, findings that sug- 
gested that the GA6 antibody was not able to prevent 
neutrophil extravasation i to the vein wall but was 
effective in limiting monocyte and lymphocyte (p = 
0.03) influx. However, in the CY1748 treated 
group, there was an increase of only 16 + 4 leuko- 
cytes in the vein wall (p = 0.05, although ANOVA 
between the three groups was not significant) com- 
prised of 6 2 3 neutrophils, 5 ± 1 monocytes, and 
5 -+- 4 lymphocytes, uggesting that this antibody was 
better at limiting an inflammatory cell influx (specif- 
ically neutrophils and monocytes) than the GA6 an- 
tibody in areas of stasis plus catheter presence with 
injury. 
MRV compared with morphometrics.  When 
comparing Gd enhancement to leukocyte migration 
into the IVC, there was an association between Gd 
enhancement and absolute monocyte count (r = 
0.71, r 2 = 0.5 0, p = 0.01 ) and Gd enhancement and 
absolute total inflammatory cell count (r = 0.65, r 2 
= 0.42, p = 0.02) and a trend between Gd enhance- 
ment and total inflammatory cell count adjusted for 
SVC control (r = 0.56, r 2 = 0.31, p = 0.06). 
Likewise, there was an association between edema 
( I /R)  and absolute lymphocyte count (r = 0.60, 
r 2 = 0.36, p = 0.041), I /R  and total inflammatory 
cell count (r = 0.63, t a = 0.40, p = 0.028), and I//R 
and total inflammatory cell count adjusted for SVC 
control (r = 0.57, r 2 = 0.32, 20 = 0.05). For the RI 
vein, no significant associations were found between 
MRV and morphometrics. 
Cytokine expression within the IVC wall. To 
quantify the expression of cytoldnes in the vein wall, 
as an indicator of possiblc vein wall inflammatory 
signaling mechanisms, we measured cytokines in the 
vein wall, as compared with the SVC control vein 
wall. 
When the IVC and RI vein segments were exam- 
ined together and the SVC control values were sub- 
tracted, IL-8 (a neutrophil chemoattractant d acti- 
vating protein) was the predominant cytokine 
identified. In the control baboons, there was 253 + 
197 pg/ml  vs 84 + 42 pg/ml  of IL-8 in the GA6 
group (p = 0.02, control vs GA6). For the CY1748 
group, the corresponding value was 1401 + 372 
pg/ml  for IL-8 (p = 0.05, CY1748 vs control). Vein 
wall PF-4 (a marker ofplatelet activation, degranula- 
tion) was decreased in spccimens of baboons treated 
with both antibodies, as compared with the control 
specimens (control, 424 ± 205 pg/ml  vs GA6, 19 2 
10 pg/ml  and CY1748, 19 ± 1 pg/ml;  p < 0.05 for 
both). Cytokines that were not elevated in the con- 
trol or GA6 groups (MGP-1, IL-6, and IRAP) were 
elevated in the CY1748 group (MCP-1,283 ± 21 
pg/ml;  IL-6, 275 + 176 pg/ml;  and IRAP, 296 ± 
33 pg/ml).  
Thrombus formation. When all IVC segments 
and RI specimens were examined for the presence or 
absence ofthrombus, 29 of 50 segments (58%) in the 
control group were positive for thrombus (Table 
IV). In comparison, both antibody treated groups 
had less thrombus formation in these same segments, 
15 of 50 (30%; p < 0.01). Examining the mid-IVC 
alone (area of stasis injury), 6 of  10 (60%) control 
segments vs 1 of 10 (10%) segments for each of the 
antibody treated groups were positive for thrombus 
(p < 0.05) suggesting excellent protection from 
thrombus formation in the antibody-treated groups. 
When all IVC segments were considered, without 
the RI veins, 19 of 40 control specimens (48%), 10 of 
40 (25%, p = 0.09) GA6 specimens, and 9 of 40 
(23%, p < 0.05) CY1748 specimens were positive for 
thrombus. 
Importantly, at the IVC balloon sites associated 
with greatest direct vessel wall injury, no differences 
in thrombus formation between the P-selectin anti- 
body treated baboons and the control groups were 
observed (control, 8 of 20, 40%; GA6, 7 of 20, 35%; 
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CY1748, 6 of 20, 30%, ns). However, at the RI veins 
with catheter presence and presumably less-direct 
vein wall injury than the balloon injury sites, 10 o f l0  
specimens in the control group versus 5 of 10 in the 
GA6 and 6 of 10 in the CY1748 treated group were 
positive for thrombus (p < 0.05 for each). There was 
no thrombus noted in the left iliac vein in any of the 
three groups. 
Coagulation profile. Examination of the coag- 
ulation profile (calculated as the percentage change 
from baseline value) revealed that the GA6-treated 
group had no elevation in aPTT at day 2 or day 6. 
There was minimal elevation oted on day 13 (+ 7%) 
that was not statistically significant and that returned 
to below baseline value by 2 months. However, for 
the CY1748 treated group, there was mild elevation 
in the aPTT at day 2 (+23% change from baseline; 
p = 0.05) and at day 6 (+2%, ns) that returned to 
near baseline value by day 13 (+1% change from 
baseline). TCTs for both antibody treated groups 
revealed no elevation from baseline values at days 2, 
6, or 13. In addition, serum platelet counts for both 
GA6- and CY1748-treated baboons rose above base- 
line values at day 2 (GA6, 283,000 to 307,000; 
CY1748, 238,000 to 247,000), whereas platelet 
counts at day 2 in the controls increased from 
161,000 to 245,000. 
DISCUSSION 
Our findings demonstrate hat neutralization of
P-selectin in a primate model of venous stasis and 
thrombosis results in decreased vein wall inflamma- 
tion, cytokine production, and thrombus formation. 
The P-selectin molecule is a multidomain structure 
having an amino terminal C-type lectin domain, an 
epidermal growth factor like domain, and a variable 
number of repeats resembling complement-binding 
proteins followed by a transmembrane domain and 
short cytoplasmic tail. 2° Differential neutralization f
P-selectin was associated with varying degrees of vein 
wall inflammatory inhibition. However, both anti- 
bodies were equally effective inhibiting thrombus 
formation. 
Increased recognition of the complex nature of 
various leukocyte cell adhesion molecules and their 
critical role in physiologic and pathophysiologic in-
flammation has stimulated ongoing investigation as
to possible areas to target herapy. 9,1° In this study, 
we focus on the earliest expressed adhesion mole- 
cule, the membrane glycoprotein P-selectin, nor- 
mally found in a-granules ofplatelets and in Weibel- 
Palade bodies of endothelial cells. 21-23 With cellular 
activation, granules fuse with the plasma membrane, 
translocating P-selectin to the surface membrane, 
permitting leukocytes and platelets to interact and 
roll. This process allows reversible binding of leuko- 
cytes and platelets to endothelial cells, and platelets 
to leukocytes. Irreversible binding subsequently oc- 
curs after [31 and [32 integrin expression on leuko- 
cytes and adhesion to their ligands/receptors on
endothelial surfaces. 24 
Our results demonstrate that he GA6 P-selectin- 
blocking antibody appears to be effective to inhibit 
the increase in neutrophils, lymphocytes, and total 
inflammatory cells in an area of pure stasis injury 
(Table III). However, in areas of stasis plus catheter 
presence, the GA6 antibody was not as effective as 
CY1748 in preventing neutrophil emigration into 
the vein wall despite xcellent inhibition of Gd en- 
hancement oted by MRV. This suggests a mecha- 
nism independent of the inhibition of neutrophil 
extravasafion for GA6's anti-inflammatory effect, 
whereas CY1748 does inhibit leukocyte migration 
in such areas. 
Although diagnostic techniques to identify the 
presence or absence of DVT have been clearly de- 
fined through clinical practice, little has been done to 
evaluate the extent of the vein wall injury/inflamma- 
tion associated with thrombus formation. Gd-en- 
hanced MRV may allow quantitation of the throm- 
bus associated vein wall and perivenous tissue injury 
(Fig. 2). Gd chelates are paramagnetic heavy metal 
agents that decrease the T1 relaxation times of in- 
flammatory loci, resulting in enhancement i  an area 
of inflammation. In addition, Gd is thought o ex- 
travasate into areas of leaky capillary beds in response 
to an inflammatory stimulus. 19 It appears that in 
areas of stasis only, such as the IVC in the present 
study, both antibodies were effective in limiting the 
amount of Gd enhancement, but the GA6 antibody 
was slightly more effective than the CY1748 anti- 
body at the earlier timepoints. However, in areas of 
stasis plus direct catheter presence such as the RI 
vein, the GA6 antibody appeared to be more effica- 
cious in preventing Gd enhancement compared with 
the CY1748 antibody and controls. Similar results 
were noted examining the amount of vein wall and 
perivenous tissue edema. In addition, MRV posi- 
tively correlated with inflammatory cell extravasation 
in an area of venous tasis but was poorly correlated 
in an area ofstasis plus catheter presence, the catheter 
presumably eading to greater direct venous wall in- 
jury. 
A chemotactic gradient present within the vein 
wall is thought to be one of the driving mechanisms 
responsible for leukocyte influx. In the present study 
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Fig. 2. MRV with Gd enhancement of he IVC and RI vein of a control baboon, GA6-treated 
baboon, and CY1748-treated baboon, all at day 2 after thrombus induction. In the control 
baboon, IVC and RI segments (A and B), Gd enhancement (closed arrows) is noted involving 
the vein wall segments and perivenous adventitial tissue, associated with intraluminal clot. In the 
GA6-treated baboon (C and D) and the CY1748-treated baboon (E and F), little Gd enhance- 
ment was noted as compared with the control group. 
we have shown that IL-8 and PF-4, members of the 
CXC chemokine family, were significantly elevated in 
the vein wall during thrombosis. IL-8, an 8.0 kD 
polypeptide, produced by many cell types including 
fibroblasts, neutrophils, and monocytes is a potent 
chemoattractant for neutrophils.25 Like other known 
neutrophil chemotactic factors, IL-8 can activate 
neutrophils via a GTP-binding protein that appears 
to be both Ca2 +- and protein kinase C-dependent. z5 
Interestingly, in baboons treated with the GA6 anti- 
body, our study revealed that in the area ofstasis plus 
catheter presence with injury (RI), neutrophil infil- 
tration was elevated espite the fact that IL-8 was 
significantly ower as compared with saline controls. 
Although studies have shown that antibody to P- 
selectin may inhibit leukosequestration, 26 our find- 
ings suggests hat the GA6 antibody may have a 
mechanism of inflammatory inhibition separate from 
the inhibition of leukocyte migration, allowing neu- 
trophil infiltration independent of IL-8, but without 
neutrophil activation. 
PF-4, present in platelet a-granules, 27likcly func- 
tions in the thrombus/inflammation relationship 
given the role in which platclets play in thrombus 
formation and propagation. Both neutralizing anti- 
bodies to P-selecfin decreased the amount of PF-4 in 
the vein walls, which suggests the effectiveness of 
both antibodies against platelet activation and dc- 
granulation. Howcver, the increase in other cyto- 
kines induced by C¥1748, such as MCP-1, IL-6, and 
IRAP, suggest hat this intact antibody may have 
induced cytokine xpression. 
Thrombin generation after an inciting event such 
as DVT with venous stasis, endothelial hypoxia, and 
vcin wall injury leads to upregulation of P-selec- 
tin. 11,12 This P-selectin expression results in further 
amplification of the vein wall inflammatory esponse 
with propagation of thrombosis. Our results demon- 
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strate that neutralization of P-selecrin before the 
initiation of the thrombotic stimulus does decrease 
thrombus formation. Both antibodies were equally 
effective in limiting thrombus formation as compared 
with the control group in areas of pure stasis injury. 
Importantly, the area of stasis injury located between 
the balloon catheters most closely reflects clinical 
DVT formation. 28 However, in areas with significant 
vessel wall injury (i.e., the balloon sites), there 
seemed to be minimal protection in thrombus for- 
marion between the P-selectin antibodies and the 
control group, whereas in areas with catheter pres- 
ence and presumably ess direct vein wall injury (the 
RI vein), some protection in thrombus formation 
remained. This suggests that by direct vein wall 
trauma, endothelial cell-derived P-selectin may be 
eliminated, thus removing the P-selecrin target. 
Neither antibody appeared to show any detri- 
mental effect on the coagulation profile of the ba- 
boons as measured with aPTTs and TCTs, except for 
the aPTT at day 2 for CY1748, which was slightly 
prolonged; there was no obvious bleeding tendency. 
In comparing the aPTTs and TCTs of the three 
groups, there were no differences. 
Previous studies have shown that antibody to 
P-selectin prevents neutrophil adhesion to the sur- 
face of activated adherent platelets, 24,29 decreases the 
release of cathepsin G from activated neutrophils, 29
inhibits P-selecrin expression on endothelial cells and 
platelets decreasing platelet-platelet and platelet-leu- 
kocyte adhesion, 29,a° downregulates protein ldnase C 
(PKC) activation from endothelial cells and plate- 
lets, 31 inhibits tissue factor expression on mono- 
cytes, 12 inhibits the upregulation of the nuclear tran- 
scription factor Nf-kB 32 important for cytokine 
production, and may antagonize complement activa- 
tion? 3 Our study suggests that antibody to P-selec- 
tin, in this model of DVT-induced inflammation, 
functions consistently with both leukocyte xtravasa- 
tion independent (GA6) and dependent (CY1748) 
mechanisms and also eliminates platelet activation as 
assessed by PF-4 levels. 
Finally, advances in our knowledge of the effects 
of inhibition of the interactions among leukocytcs, 
endothelial cells, and platelets may possibly be useful 
clinically in reducing subsequent vein wall injury and 
resultant CVI. Although prophylaxis against DVT 
has been thoroughly studied in high-risk patients, 
there remains a subset of patients who have not 
benefited from standard prophylactic anticoagula- 
tion techniques, 2 necessitating further investigation 
into alternative interventions. For example, despite 
the best available prophylaxis, DVT still occurs in 10 
to 15% of cases during hip and knee replacement 
surgery. Leukocyte adhesion eutralization may pro- 
vide an alternative prophylactic intervention for 
those patients who are very high-risk for the develop- 
ment of DVT and may be of benefit, over and above 
standard anticoagulant prophylaxis with heparin or 
low molecular weight heparin, with possibly a de- 
creased risk of hemorrhage. 
CONCLUSION 
Our results indicate that neutralization ofP-selectin 
has an impact on the degree of thrombus formation 
and the severity of the associated vein wall inflamma- 
tory response. Furthermore, these effects may be mod- 
ulated at the molecular level depending on what por- 
tion of P-selectin is neutralized, although the 
differences between the two antibodies may be intrinsic 
to the antibodies themselves. Further study of the effec- 
tiveness of selectin neutralization i therapeutic, not 
merely prophylactic application (i.e., given after DVT 
has begun) is also warranted. 
Differential neutralization of P-selectin by target- 
ing either the lectin-epidermal growth factor domain 
(GA6) or the complement consensus repeat region 
(CY1748) is associated with varying degrees of inhi- 
bition of vein wall inflammation, although both an- 
tibodies inhibit inflammation compared with control 
in areas of pure venous tasis. Antibody to P-selectin 
(GA6) appears to have a mechanism of inflammatory 
inhibition separate from the inhibition of neutrophil 
emigration, in areas of stasis plus catheter presence 
with injury. Antibody tO P-selectin (CY1748) ap- 
pears to have a mechanism of inflammatory inhibi- 
tion consistent with inhibition of leukocyte migra- 
tion, in areas of stasis plus catheter presence with 
injury. Antibody to P-selectin (GA6 and CY1748) 
contributes to decreased thrombus formation during 
venous thrombosis. Antibody to P-selectin (GA6 and 
CY1748) has minimal potential for bleeding compli- 
cations. 
We wish to acknowledge and thank Dr. Ronald She- 
busld of Pharmacia & Upjohn Corporation for providing 
the CY1748 antibody used in this study. 
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DISCUSSION 
Dr. Timothy B. Baxter (Omaha, Neb.). Dr. Down- 
ing and his colleagues from Michigan have presented an 
elegant study of an important clinical problem that we all 
see, DVT. In this study, they have moved from a rodent 
model to a primate model that I think we would all agree 
provides data that may be more relevant o the patients 
that we see who have DVT. In doing so, one of the 
problems is that you are only able to study a much smaller 
number of baboons. They have studied the role of P- 
selectin in the process ofthrombus formation and its asso- 
ciated inflammation, which we are learning may be impor- 
tant in both the acute and chronic sequelae of DVT. They 
assess the role of P-selectin by using two antibodies that 
bind to different portions of the extramembrane tail of the 
molecule. Because P-selectin is important in adhesion of 
both platelets and neutrophils to endothelium, it is reason- 
able to hypothesize that blocldng its receptor would inhibit 
both thrombus formation and neutrophil attachment. I 
believe that the data are convincing and support he con- 
clusion that vein wall thrombus is reduced by both of these 
antibodies. The effect on white blood cell infiltration also 
appears to be fairly significant, although not as convincing 
as the data on thrombus formation. 
I have three questions for you. First of all, there is a 
tremendous amount of data presented in the paper. Regard- 
ing the statistical nalysis, I would like to know whether in 
your comparisons you took into account he three study 
groups. It appears that in some of the comparisons, a t test 
was used. As you increase the number of study groups, you 
have to increase the stringency of your test. 
My second question is about he ability of the antibody 
to block attachment of the thrombus. This relates poten- 
tially to the clinical use of these agents down the road. If 
the antibody does not actually prevent he formation of 
thrombus in areas of stasis but prevents the attachment of 
thrombus in those areas, might this create amore unstable 
and mobile thrombus? Did you look for evidence of pul- 
monary embolus, and were there any differences between 
the groups? 
Finally, platelet and neutrophil adhesion trigger a cas- 
cade of events that is essential to normal wound healing. 
This again relates to the possible role of P-selectin antibod- 
ies in the future for DVT prophylaxis during the perioper- 
ative period. Would you expect P-selectin to affect healing, 
and were there any effects evident in terms of wound 
healing in this animal model? 
This is an elegant study and an outstanding presenta- 
tion. Targeting the inflammatory response to DVT could 
finally provide a means of preventing the long-term se- 
quelae of DVT. I congratulate Dr. Downing and his col- 
leagues and heartily concur with the selection of this paper 
for the Guthrie Award. 
Dr. L. Joseph Downing. First, you are absolutely 
right that in carrying out a study of this nature using 12 
primates we were somewhat limited in the number that we 
could ultimately do. But that being the case, we did make 
comparisons between the control and each of the treat- 
ment groups using standard t test analysis if, by ANOVA, 
there were differences between the three groups. 
In terms of whether the antibody would make the 
thrombus more unstable and perhaps more mobile, which 
ultimately could potentially lead to pulmonary embolism, 
we did at the time of sacrifice harvest the pulmonary arter- 
ies and looked for any evidence of pulmonary embolism. 
We did not see evidence of pulmonary embolism in any of 
the baboons. 
Yes, the P-selectin antibody, specifically GA6, has been 
tested in a number of inflammatory models, and it is 
possible that it may have a role in other models or other 
disease processes of inflammation. We did not actually see 
any effects as far as wound healing is concerned in our 
model, particularly at the sldn groin incision sites where the 
lower catheter was placed. 
As far as speculating what this antibody would do in a 
normal patient, hopefully that will be the next study. I 
suspect that as far as in a prophylactic setting, the antibody 
may have a role, particularly in patients who are at high risk 
for venous thrombosis, such as the orthopedic hip and 
knee patients. This antibody in conjunction with standard 
anticoagulation therapy may also lead to or enable a de- 
crease in the amount of standard or low molecular weight 
heparin that is used. 
